𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells

✍ Scribed by Wang, Yue Dan; De Vos, John; Jourdan, Michel; Couderc, Guilhem; Lu, Zhao-Yang; Rossi, Jean-François; Klein, Bernard

Book ID
110066554
Publisher
Nature Publishing Group
Year
2002
Tongue
English
Weight
403 KB
Volume
21
Category
Article
ISSN
0950-9232

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

High glucose and hyperosmolarity increas
High glucose and hyperosmolarity increase heparin-binding epidermal growth factor-like growth factor (HB-EGF) production in cultured human aortic endothelial cells
✍ Hideki Asakawa; Jun-Ichiro Miyagawa; Shigeki Higashiyama; Katsutoshi Goishi; Tos 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 900 KB

## Abstract Heparin‐binding epidermal growth factor‐like growth factor (HB‐EGF) has been shown to be a potent smooth muscle cell (SMC) mitogen and chemoattractant, and might be a candidate factor for the progression of atherosclerosis. We have investigated the effects of high glucose and hyperosmol

Co-expression of heparin-binding EGF-lik
Co-expression of heparin-binding EGF-like growth factor and related peptides in human gastric carcinoma
✍ Markus Naef; Munehiro Yokoyama; Helmut Friess; Markus W. Büchler; Murray Korc 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 French ⚖ 898 KB

Heparin-binding epidermal growth factor (EGF)-like growth factor (HB-EGF) is a member of the EGF family of polypeptide growth factors, which includes EGF, transforming growth faaor a (TGF-a), amphiregulin (AR) and betacellulin (BTC). To assess the potential role of HB-EGF in human gastric carcinomas

Induction of heparin-binding EGF-like gr
Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells
✍ Faye M. Johnson; Babita Saigal; Nicholas J. Donato 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 459 KB

Imatinib mesylate is a tyrosine kinase inhibitor of the ABL, platelet-derived growth factor receptor (PDGFR), and c-kit kinases. Inhibition of BCR-ABL and c-kit accounts for its clinical activity in leukemia and sarcoma, respectively. In this report, we describe other cellular targets for imatinib.